JP7829242B2 - 最適化ペプチドワクチンの組成物および方法 - Google Patents

最適化ペプチドワクチンの組成物および方法

Info

Publication number
JP7829242B2
JP7829242B2 JP2023530750A JP2023530750A JP7829242B2 JP 7829242 B2 JP7829242 B2 JP 7829242B2 JP 2023530750 A JP2023530750 A JP 2023530750A JP 2023530750 A JP2023530750 A JP 2023530750A JP 7829242 B2 JP7829242 B2 JP 7829242B2
Authority
JP
Japan
Prior art keywords
peptide
hla
seq
peptides
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023530750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551204A5 (enExample
JP2023551204A (ja
Inventor
ギフォード，デイビッド
カーター，ブランドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Think Therapeutics Inc
Original Assignee
Think Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/100,630 external-priority patent/US11058751B1/en
Priority claimed from US17/114,237 external-priority patent/US11161892B1/en
Priority claimed from US17/389,875 external-priority patent/US11421015B2/en
Application filed by Think Therapeutics Inc filed Critical Think Therapeutics Inc
Publication of JP2023551204A publication Critical patent/JP2023551204A/ja
Publication of JP2023551204A5 publication Critical patent/JP2023551204A5/ja
Application granted granted Critical
Publication of JP7829242B2 publication Critical patent/JP7829242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023530750A 2020-11-20 2021-11-19 最適化ペプチドワクチンの組成物および方法 Active JP7829242B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US17/100,630 US11058751B1 (en) 2020-11-20 2020-11-20 Compositions for optimized RAS peptide vaccines
US17/100,630 2020-11-20
US17/114,237 2020-12-07
US17/114,237 US11161892B1 (en) 2020-12-07 2020-12-07 Method of compact peptide vaccines using residue optimization
US17/336,960 US11235039B1 (en) 2020-11-20 2021-06-02 Immunogenic compositions comprising nucleic acids for RAS peptides
US17/336,960 2021-06-02
US17/389,875 US11421015B2 (en) 2020-12-07 2021-07-30 Method of compact peptide vaccines using residue optimization
US17/389,875 2021-07-30
US202163249235P 2021-09-28 2021-09-28
US63/249,235 2021-09-28
PCT/US2021/060013 WO2022109220A1 (en) 2020-11-20 2021-11-19 Compositions and methods for optimized peptide vaccines

Publications (3)

Publication Number Publication Date
JP2023551204A JP2023551204A (ja) 2023-12-07
JP2023551204A5 JP2023551204A5 (enExample) 2024-10-28
JP7829242B2 true JP7829242B2 (ja) 2026-03-13

Family

ID=81708071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530750A Active JP7829242B2 (ja) 2020-11-20 2021-11-19 最適化ペプチドワクチンの組成物および方法

Country Status (5)

Country Link
EP (1) EP4247401A4 (enExample)
JP (1) JP7829242B2 (enExample)
AU (1) AU2021381384A1 (enExample)
CA (1) CA3202227A1 (enExample)
WO (1) WO2022109220A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240131133A1 (en) * 2022-10-10 2024-04-25 Think Therapeutics, Inc. Compositions and methods for optimized kras peptide vaccines
CN116130005B (zh) * 2023-01-30 2023-06-16 深圳新合睿恩生物医疗科技有限公司 多表位疫苗的串联设计方法及装置、设备、存储介质

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018145020A1 (en) 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CN108395479A (zh) 2017-02-06 2018-08-14 高军 一种有关kras基因突变的t细胞受体
JP2019527555A (ja) 2016-08-02 2019-10-03 アメリカ合衆国 抗ｋｒａｓ−ｇ１２ｄ ｔ細胞受容体
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
WO2020210202A1 (en) 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884893B2 (en) * 2012-05-21 2018-02-06 Distributed Bio, Inc. Epitope focusing by variable effective antigen surface concentration
WO2016154047A2 (en) * 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
EP3294324A1 (en) * 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
CA2986235A1 (en) * 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
EP3532070A1 (en) * 2016-10-26 2019-09-04 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) * 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019527555A (ja) 2016-08-02 2019-10-03 アメリカ合衆国 抗ｋｒａｓ−ｇ１２ｄ ｔ細胞受容体
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
WO2018145020A1 (en) 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CN108395479A (zh) 2017-02-06 2018-08-14 高军 一种有关kras基因突变的t细胞受体
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2020210202A1 (en) 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUONAGURO Luigi and TAGLIAMONTE Maria，Selecting Target Antigens for Cancer Vaccine Development，Vaccines，2020年10月17日，Vol.8, No.615，p.1-14
IIIZUMI Susumu et al.，Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations，Cancers，2019年02月24日，Vol.11, No.266，p.1-14
WAN Yuhua et al.，Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models，Frontiers in Oncology，2020年08月12日，Vol.10, Article 1326，p.1-14
ZIRLIK Mauerer Katja et al.，Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide，BLOOD，2006年12月01日，Vol.108, No.12，p.3865-3870

Also Published As

Publication number Publication date
AU2021381384A1 (en) 2023-06-22
EP4247401A1 (en) 2023-09-27
EP4247401A4 (en) 2025-06-11
WO2022109220A1 (en) 2022-05-27
JP2023551204A (ja) 2023-12-07
CA3202227A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
US11464837B2 (en) Immunogenic compositions comprising nucleic acids for RAS peptides
AU2022264493A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
US11161892B1 (en) Method of compact peptide vaccines using residue optimization
JP7585195B2 (ja) ネオエピトープを選択する方法
US20250222087A1 (en) Compositions for optimized bcr-abl peptide vaccines
AU2021381384A1 (en) Compositions and methods for optimized peptide vaccines
Odales et al. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer
US20240383963A1 (en) Method of compact peptide vaccines using residue optimization
US20250333448A1 (en) Compositions for optimized influenza peptide vaccines
US20240131133A1 (en) Compositions and methods for optimized kras peptide vaccines
US20250235526A1 (en) Compositions and methods for optimized hiv peptide vaccines
US20260041763A1 (en) Compositions and methods for optimized covid peptide vaccines
HK40100731A (zh) 用於优化的肽疫苗的组合物和方法
US20240269250A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
HK40101953A (zh) 利用残基优化技术优化肽疫苗的组合物和方法
WO2025064339A1 (en) Compositions and methods for optimized peptide vaccines
KR20220083063A (ko) 전립선 항원 단백질로부터 분리된 에피토프 및 이를 포함하는 전립선암 다중-에피토프 백신 조성물
EP4311834A1 (en) Peptides and combinations of peptides for use in immunotherapy against ropharyngeal squamous cell carcinoma (opscc) and other cancers
AU2017227104A1 (en) Human myosin peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260224

R150 Certificate of patent or registration of utility model

Ref document number: 7829242

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150